Ren P, Tiede C, Fanning S, Adams T, Speirs V, Nelson E
Biophys J. 2022; 121(19):3651-3662.
PMID: 35778844
PMC: 9617163.
DOI: 10.1016/j.bpj.2022.06.028.
Gu G, Tian L, Herzog S, Rechoum Y, Gelsomino L, Gao M
Oncogene. 2020; 40(5):997-1011.
PMID: 33323970
PMC: 8020875.
DOI: 10.1038/s41388-020-01563-x.
Zhao F, Yang G, Feng M, Cao Z, Liu Y, Qiu J
J Cell Mol Med. 2020; 24(14):7686-7696.
PMID: 32468698
PMC: 7348177.
DOI: 10.1111/jcmm.15348.
Lei J, Anurag M, Haricharan S, Gou X, Ellis M
Breast. 2019; 48 Suppl 1:S26-S30.
PMID: 31839155
PMC: 6939855.
DOI: 10.1016/S0960-9776(19)31118-X.
Rodriguez D, Ramkairsingh M, Lin X, Kapoor A, Major P, Tang D
Cancers (Basel). 2019; 11(7).
PMID: 31336602
PMC: 6678134.
DOI: 10.3390/cancers11071028.
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.
Pejerrey S, Dustin D, Kim J, Gu G, Rechoum Y, Fuqua S
Horm Cancer. 2018; 9(4):215-228.
PMID: 29736566
PMC: 9680193.
DOI: 10.1007/s12672-017-0306-5.
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Palmieri C, Stein R, Liu X, Hudson E, Nicholas H, Sasano H
Breast Cancer Res Treat. 2017; 165(2):343-353.
PMID: 28612226
PMC: 5543190.
DOI: 10.1007/s10549-017-4328-z.
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis.
Bado I, Gugala Z, Fuqua S, Zhang X
Oncogene. 2017; 36(32):4527-4537.
PMID: 28368409
PMC: 5552443.
DOI: 10.1038/onc.2017.94.
Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry.
Qian F, Feng Y, Zheng Y, Ogundiran T, Ojengbede O, Zheng W
Hum Genet. 2016; 135(10):1145-59.
PMID: 27380242
PMC: 5021583.
DOI: 10.1007/s00439-016-1707-1.
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Gelsomino L, Gu G, Rechoum Y, Beyer A, Pejerrey S, Tsimelzon A
Breast Cancer Res Treat. 2016; 157(2):253-265.
PMID: 27178332
PMC: 5510243.
DOI: 10.1007/s10549-016-3829-5.
ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action.
Gu G, Fuqua S
Clin Cancer Res. 2015; 22(5):1034-6.
PMID: 26700205
PMC: 4775407.
DOI: 10.1158/1078-0432.CCR-15-2549.
Retrospective analysis of metastatic behaviour of breast cancer subtypes.
Dilara Savci-Heijink C, Halfwerk H, Hooijer G, Horlings H, Wesseling J, van de Vijver M
Breast Cancer Res Treat. 2015; 150(3):547-57.
PMID: 25820592
PMC: 4383810.
DOI: 10.1007/s10549-015-3352-0.
Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight.
Fuqua S, Gu G, Rechoum Y
Breast Cancer Res Treat. 2014; 144(1):11-9.
PMID: 24487689
PMC: 4123761.
DOI: 10.1007/s10549-014-2847-4.
An immunohistochemical study on the expression of sex steroid receptors in canine mammary tumors.
Louis L, Varshney K, Nair M
ISRN Vet Sci. 2013; 2012:378607.
PMID: 23738123
PMC: 3658582.
DOI: 10.5402/2012/378607.
An exonuclease III protection-based electrochemical method for estrogen receptor assay.
Zhu S, Cao Y, Xu Y, Yin Y, Li G
Int J Mol Sci. 2013; 14(5):10298-306.
PMID: 23681011
PMC: 3676839.
DOI: 10.3390/ijms140510298.
Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions.
Yardley D
Breast Cancer (Auckl). 2013; 7:7-22.
PMID: 23492649
PMC: 3579426.
DOI: 10.4137/BCBCR.S10071.
Association of estrogen receptor-α A908G (K303R) mutation with breast cancer risk.
Abbasi S, Rasouli M, Nouri M, Kalbasi S
Int J Clin Exp Med. 2012; 6(1):39-49.
PMID: 23236557
PMC: 3515972.
Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells.
Haim K, Weitzenfeld P, Meshel T, Ben-Baruch A
Neoplasia. 2011; 13(3):230-43.
PMID: 21390186
PMC: 3050866.
DOI: 10.1593/neo.101340.
Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP.
Sanchez A, Flamini M, Baldacci C, Goglia L, Genazzani A, Simoncini T
Mol Endocrinol. 2010; 24(11):2114-25.
PMID: 20880986
PMC: 5417375.
DOI: 10.1210/me.2010-0252.
Regulators affecting the metastasis suppressor activity of Nm23-H1.
Kim H, Youn B, Kim T, Kim S, Shin H, Kim J
Mol Cell Biochem. 2009; 329(1-2):167-73.
PMID: 19377884
DOI: 10.1007/s11010-009-0109-2.